GSK3B and neoplasm: Preclinical studies of single and chronic oral dosing of AZD5363 in mice have demonstrated dose-dependent inhibition of AKT substrate phosphorylation (GSK3β and PRAS40), tumour cell proliferation, and tumour growth in xenograft models [6].